Once-monthly long-acting olanzapine for adults with Schizophrenia.
WELTRUZA™
WELTRUZA™ is the only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of adults with schizophrenia.
Approved by the U.S. FDA in October 2026, WELTRUZA™ is the second product powered by Medincell’s BEPO® technology to receive FDA approval.
WELTRUZA™ does not require loading doses or oral supplementation at treatment initiation and eliminates the need for post-injection monitoring, addressing a major, long-standing gap in schizophrenia care.
WELTRUZA™ is a trademark of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.
Strong differentiation thanks to BEPO®
Once-monthly treatment
Available in three doses corresponding to oral olanzapine doses for treatment of schizophrenia
Immediate onset of action
No loading doses and no oral supplementation at initiation
Favorable safety profile
No mandatory post-injection monitoring period required
Small needle size
One of the smallest LAI needles used to treat schizophrenia
Injected just below the skin
Most other schizophrenia LAIs are injected into muscle
